ScoreSurgery
New England Spinal Metastasis Score (NESMS)
One-year survival prognosis in spinal metastases from the modified Bauer score, ambulation and albumin.
Updated 30 October 2026
When to use it
Patients with spinal metastases being considered for surgery, radiotherapy or conservative care.
What it needs
- No visceral metastases
- Primary tumour other than lung
- Breast, kidney, lymphoma or myeloma primary
- Single skeletal metastasis
- Ambulates independently
- Serum albumin
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 0 | 1-year mortality ≈ 93 % |
| 1 | 1-year mortality ≈ 69 % |
| 2 | 1-year mortality ≈ 45 % |
| ≥ 3 | 1-year mortality ≈ 13 % |
Practical tip
Score 0–3: higher is better. With 0 points almost no patient survived one year in the prospective cohort.
3 more practical tips in the app.
Reference
- Ghori AK, Leonard DA, Schoenfeld AJ, et al. Modeling 1-year survival after surgery on the metastatic spine. Spine J. 2015;15(11):2345-2350.
- Schoenfeld AJ, Ferrone ML, Schwab JH, et al. Prospective validation of a clinical prediction score for survival in patients with spinal metastases: the New England Spinal Metastasis Score. Spine J. 2021;21(1):28-36.
- Schoenfeld AJ, Ferrone ML, Blucher JA, et al. Prospective comparison of the accuracy of the New England Spinal Metastasis Score (NESMS) to legacy scoring systems in prognosticating outcomes following treatment of spinal metastases. Spine J. 2022;22(1):39-48.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
